A Prospective, Single-Center, Single-Arm, Exploratory Study of ¹⁷⁷Lu-LNC1010 Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors.

Authors

Wei Guo, Chunlei Fan, Yuhang Chen, Shan Yu, Guanming Yue, Tianzhi Zhao, Dan Ruan, Weizhi Xu, Hao Fu, Bishan Su, Lingyu Yu, Liang Zhao, Jingxiong Huang, Hua Wu, Jingjing Zhang, Xin Zhao, Xiaoyuan Chen, Haojun Chen

Published in

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. Sep 03, 2026. Epub Sep 03, 2026.

Abstract

Rapid radiopharmaceutical clearance limits the efficacy of peptide receptor radionuclide therapy (PRRT) for the treatment of advanced neuroendocrine tumors (NETs). In this prospective, single-center, single-arm, investigator-initiated trial, we evaluated the safety and efficacy of ¹⁷⁷Lu-LNC1010-an optimized, long-acting somatostatin analog-in patients with progressive metastatic NETs. Methods: Twenty-two patients with unresectable, metastatic NETs and disease progression despite treatment with somatostatin analogs or tyrosine kinase inhibitors were enrolled in the study. Participants received up to 4 cycles of PRRT with ¹⁷⁷Lu-LNC1010 (3.3 GBq/cycle) at 8-wk intervals. Adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 5.0. The treatment response was evaluated using RECIST 1.1. Kaplan-Meier analysis was used to estimate progression-free survival (PFS) and overall survival (OS). Results: The patients (13 men, 9 women; median age, 50.5 y) received 69 PRRT cycles in total. Treatment-related grade 3 or 4 hematologic toxicities were observed in 6 patients (27%). No grade 3 or higher nephrotoxicity or hepatotoxicity was recorded. The median absorbed tumor dose was 2.12 (interquartile range: 1.68-2.96) Gy/GBq. Response after PRRT was assessed in 18 patients. A partial response was achieved in 8 patients (44.0%), stable disease in 9 (50.0%), and progressive disease in 1 (5.6%). The objective response rate was 44.4%, and the disease control rate was 94.4%. After a median follow-up of 21.0 mo, the median PFS was 15.0 mo, and the median OS was not reached. Conclusion: PRRT with 3.3 GBq/cycle of ¹⁷⁷Lu-LNC1010 was well-tolerated and exhibited an acceptable safety profile. The objective response rate and disease control rate were high and positively correlated with improved PFS and OS. Appropriate patient selection and earlier intervention may further optimize the therapeutic benefit.

PMID:
42692826
Bibliographic data and abstract were imported from PubMed on 04 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.